Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Operating Expenses (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Operating Expenses data on record, last reported at $45.5 million in Q4 2023.

  • For Q4 2023, Operating Expenses changed N/A year-over-year to $45.5 million; the TTM value through Dec 2023 reached $190.6 million, up 173.28%, while the annual FY2024 figure was $196.9 million, 3.29% up from the prior year.
  • Operating Expenses reached $45.5 million in Q4 2023 per CGEM's latest filing, up from $44.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $62.8 million in Q1 2023 and bottomed at $5.5 million in Q1 2020.
  • Average Operating Expenses over 4 years is $29.1 million, with a median of $30.9 million recorded in 2020.
  • Peak YoY movement for Operating Expenses: soared 217.11% in 2021, then grew 1.34% in 2023.
  • A 4-year view of Operating Expenses shows it stood at $29.2 million in 2020, then grew by 17.74% to $34.3 million in 2021, then grew by 8.03% to $37.1 million in 2022, then rose by 22.58% to $45.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $45.5 million in Q4 2023, $44.8 million in Q3 2023, and $37.6 million in Q2 2023.